Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Rabeprazole Sodium Intermediates Rabeprazole Sodium CAS 117976-90-6 Rabeprazole Hydroxy Compound CAS 675198-19-3 Rabeprazole Chloride Compound CAS 153259-31-5| Item | Specifications |
| Appearance | White to Slightly Pale Yellow Crystal or Powder; Hygroscopic |
| Infrared Spectrum | Conforms to Structure |
| Proton NMR Spectrum | Conforms to Structure |
| ICP | Confirms Sodium Component |
| Solubility | Completely Soluble in Water; Very Soluble in Ethanol, Chloroform; Soluble in Methanol |
| pH | 9.5~12.0 |
| Loss on Drying | <1.00% |
| Heavy Metals | <20ppm |
| Related Substances | (HPLC) |
| Impurity A | <0.80% |
| Unspecified Impurities | <0.20% |
| Total Impurities | <1.00% |
| Residual Solvents | (GC) |
| Methylene Chloride | <600ppm |
| Ethanol | <5000ppm |
| Isopropyl Ether | <5000ppm |
| Acetone | <5000ppm |
| Microbial Limit | |
| Aerobe Count | ≤1000CFU/g |
| Mold and Yeasts Count | ≤100CFU/g |
| E. Coli | Absent for per gram |
| Purity / Analysis Method | >99.5% (HPLC, Dried Basis) |
| Test Standard | Enterprise Standard |
| Usage | API for Anti-Ulcer |
Description:
Specifications:
Package & Storage:
| Chemical Name | Rabeprazole Sodium |
| Synonyms | 2-([4-(3-Methoxypropoxy)-3-Methylpyridin-2-yl]methylsulfinyl)-1H-Benzo[d]imidazole; Pariprazole |
| CAS Number | 117976-90-6 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C18H20N3NaO3S |
| Molecular Weight | 381.42 |
| Melting Point | 140.0~141.0℃ |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Rabeprazole Sodium (CAS: 117976-90-6) is a proton pump inhibitor that suppresses gastric acid production in the stomach. It has several medical uses: the management of conditions that involve excess gastric acid production (e.g. Zollinger-Ellison syndrome), conditions that are worsened by gastric acid (e.g. ulcerations of the gastrointestinal tract), and conditions involving prolonged exposure to gastric acid (e.g. symptomatic gastroesophageal reflux disease). Rabeprazole is also useful alongside antibiotic therapy for the treatment of the pathogen Helicobacter pylori, which otherwise thrives in acidic environments. Thus, Rabeprazole Sodium is FDA approved for the treatment of symptomatic GERD in adolescents and adults, healing duodenal ulcers in adults, eradication of Helicobacter pylori, and pathologic hypersecretory conditions. Rabeprazole Sodium suppresses the production of acid in the stomach by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell.
